StockData
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3029% below fair value
$1.91+0.10 (+5.52%)

Close on Nov 17, 2026Market cap $22.11MP/E –Yield –

TherapeuticsMD pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

TherapeuticsMD's pe ratio was 101.5× on Jul 31, 2026, against 0.2× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 2026101.5×+20.0
2025Dec 31, 202581.5×+81.1
2024Jan 31, 20240.4×+0.0
2023Dec 29, 20230.4×–

More TherapeuticsMD figures

See a number that looks wrong?